Bladder cancer is the fourth most common cancer in men and fifth most common cancer overall with up to 80% of tumors considered “superficial” or non-muscle invasive (NMI). The most aggressive NMI cancers invade the superficial part of the bladder, the lamina propria, and are staged T1. More accurate stratification of T1 cancers would aid both clinicians and patients to make better treatment decisions and potentially improve survival. We previously compared the genetic mutations and total mutation burden (TMB) of T1 cancers that are responsive to BCG compared to those that progress and identified TMB as a significant predictor of progression, presumably due to increased neoantigen burden. We will test the hypothesis that the combination of genetic and immune features of a T1 cancer can predict risk of progression better than standard pathologic features. We will develop a risk stratification algorithm based on gene expression, immune and genomic signatures to predict better treatment outcomes for patients with T1 bladder cancer compared to standard pathologic staging. The development of a more precise risk stratification for T1 bladder cancer may improve the survival for patients with prospective validation in an inter-group trial.
|Effective start/end date||1/1/18 → 12/31/19|
- Northwestern Memorial Hospital (Agmt 4/2/18)